September 13, 2024 04:49 AM EDTUpdated 07:12 AM
R&D

Neu­ro­crine culls Phase 2 neu­ropsych med af­ter fail­ing to val­i­date ear­li­er da­ta

Max Bayer

Pharma Reporter

Neu­ro­crine is halt­ing fur­ther de­vel­op­ment of lu­vadax­i­s­tat af­ter it failed to im­prove cog­ni­tive im­pair­ment in pa­tients with schiz­o­phre­nia in a mid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times